Drlee wrote:Your source is a dangerous idiot. He has published antivax shit for years. I would not waste my time listening to anything this grifter says. But then, among other things, I am a scientist.
I have read this asshat elsewhere. He and Wakefield have been selling this shit for years. To a scientist, their pronouncements are idiotic. I will only waste my time on one example. He rails, hair on fire, about how the virus is mutating and blames vaccines for this. It does not work that way. Then he breathlessly says, that we will have to keep reformulating the vaccine to chase these variants. Well Duh.
Nothing to see here. Just another untrained/uneducated douche bag going off at the mouth.
What is your comment on his new article doc?
At least try to understand instead of posting emotional stuff. I´m no expert but he certainly is.
In conclusion, poor neutralizing capacity of anti-S Abs in vaccinees not only enhances their susceptibility to breakthrough infection with Omicron but is also suspicious of delaying viral clearance, thereby promoting prolonged viral shedding and potentially predisposing vaccinees to long-haul Covid while causing them to exert sustained immune pressure on viral virulence [1]. The likelihood of breakthrough infections in C-19 vaccinees will even further increase upon their re-vaccination with an updated S(Omicron)-based C-19 vaccine during the pandemic. This is because re-vaccination will boost the infection-enhancing anti-S Abs and thereby further increase the susceptibility of vaccinees to breakthrough infection. This will result in an even higher capacity of the ACE2 receptor to outcompete broadly neutralizing anti-S(Omicron) Abs for binding to the S-RBM.
Based on the mechanism explained above, it also follows that high titers of non-neutralizing infection-enhancing Abs in vaccinees who experienced a breakthrough infection with Omicron (whether or not facilitated by re-vaccination with an updated S[Omicron]-based C-19 vaccine) will prevent these individuals from exerting immune pressure on variable or conserved S-RBD neutralizing epitopes. This is to say that breakthrough Omicron infections in vaccinees, especially when re-vaccinated with an updated S(Omicron)-based C-19 vaccine during a pandemic, will cause highly vaccinated populations to exert substantial immune pressure on viral virulence (i.e., on S-NTD) [1] but not on viral infectiousness (i.e., on S-RBD). The higher the prevalence of elevated titers of non-neutralizing infection-enhancing Abs, the higher the population-level immune pressure on viral virulence and viral transmission in the host population. On the other hand, elevated titers of non-neutralizing infection enhancing Abs shorten the duration of individual protection after breakthrough infection and increase the risk for a vaccinated individual to develop long-haul Covid. It follows that i) highly vaccinated populations are now paving the way for breeding variants that will not only be highly infectious but also highly virulent in vaccinees [1] and ii) that protection of vaccinees subsequent to breakthrough infection will only be of short duration while their susceptibility to long-haul Covid will dramatically increase.